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Vascular smooth muscle cellctivated receptors (PARs) have been shown to regulate smooth muscle cell
proliferation, migration, and vascular maturation. Thrombin up-regulates expression of several proteins including
cyclooxygenase (COX)-2 in vascular smooth muscle cells (VSMCs) and contributes to vascular diseases. However,
the mechanisms underlying thrombin-regulated COX-2 expression in VSMCs remain unclear. Western blotting,
RT-PCR, and EIA kit analyses showed that thrombin induced the expression of COX-2mRNA and protein and PGE2
release in a time-dependent manner, which was attenuated by inhibitors of PKC (GF109203X and rottlerin), c-Src
(PP1), EGF receptor (EGFR;AG1478) andMEK1/2 (U0126), or transfectionwith dominant negativemutants of PKC-
δ, c-Src or extracellular regulated kinase (ERK) and ERK1 short hairpin RNA interference (shRNA). These results
suggest that transactivation of EGFR participates in COX-2 expression induced by thrombin in VSMCs. Accordingly,
thrombin stimulated phosphorylation of ERK1/2 which was attenuated by GF109203X, rottlerin, PP1, GM6001,
CRM197, AG1478, orU0126, respectively. Furthermore, this up-regulation of COX-2mRNAandproteinwas blocked
by selective inhibitors of AP-1 and NF-κB, curcumin and helenalin, respectively. Moreover, thrombin-stimulated
activation ofNF-κB,AP-1, and COX-2 promoter activity was blocked by the inhibitors of c-Src, PKC, EGFR, MEK1/2,
AP-1 and NF-κB, suggesting that thrombin induces COX-2 promoter activity mediated through PKC(δ)/c-Src-
dependent EGFR transactivation, MEK-ERK1/2, AP-1, and NF-κB. These results demonstrate that in VSMCs,
activation of ERK1/2, AP-1 and NF-κB pathways was essential for thrombin-induced COX-2 gene expression.
Understanding the regulation of COX-2 expression and PGE2 release by thrombin/PARs system on VSMCs may
provide potential therapeutic targets of vascular inﬂammatory disorders including arteriosclerosis.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionCyclooxygenase (COX) is a rate-limiting key enzyme in the
synthesis of prostaglandins (PGs) and thromboxane. In this process,
phospholipase A2 catalyzes the release of arachidonic acid (AA) from
membrane phospholipids, while COX catalyzes the conversion of AA
into PGH2, which is the common precursor of all prostanoids [1,2].
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l rights reserved.COX-2, another COX isoform, is not detectable in most normal tissues
or resting cells, but its expression can be induced by various stimuli
including cytokines, endotoxin, and growth factors to produce pro-
inﬂammatory PGs during inﬂammatory responses in several cell types
including vascular smooth muscle cells (VSMCs) [3,4]. Previous
studies have shown that COX-2 immunoreactivity is detected in
various inﬂammatory tissues including synovial macrophage and
vascular cells of patients with arthritis and atherosclerosis, respec-
tively. Several lines of evidence have further conﬁrmed COX-2 as a
major therapeutic target for the treatment of inﬂammatory disorders
such as arthritis [2,5]. Moreover, homozygous deletion of the COX-2
gene in mice leads to a striking reduction of endotoxin-induced
inﬂammation [6]. Therefore, COX-2 may play an important role in the
development of various inﬂammatory responses such as vascular
inﬂammation (i.e. atherosclerosis and hypertension).
It has been demonstrated that thrombin plays a critical role as a
signaling molecule in many inﬂammatory diseases such as athero-
sclerosis [7] which triggers platelet aggregation and activation,
increased vascular permeability, granulocyte chemotaxis, and endothe-
lial production of prothrombotic factors [8,9]. Thrombin is a serine
proteinase that activates a seven-transmembrane domain G protein-
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(PARs) byproteolytic unmaskingof the cryptic tethered ligandpresent in
the extracellular N-terminal domain [10,11]. The PARs have been
identiﬁed comprising four receptors: PAR-1, PAR-2, PAR-3, and PAR-4
[12,13]. Thrombin can activate PAR-1, PAR-3, and PAR-4, whereas PAR-2
is mainly activated by trypsin-like enzymes but not by thrombin [9,10].
The various physiological or pathogenic effects of thrombin are due to
the widespread expression of thrombin receptors in many cells [8]. In
situ hybridization has demonstrated an increase in thrombin receptor
mRNA throughout the period of neointimal and vascular lesion
development [14]. Moreover, the levels of thrombin are increased
during inﬂammatory diseases such as atherosclerosis [15] and its
proteinase activity has been implicated in the pathogenesis of many
diseases [8,15]. The PAR-1has been shown to be expressed invarious cell
types including smoothmuscle cells [10] and thrombin can induce COX-
2 expression in many cell types such as vascular endothelial cells [16].
Therefore, thrombin may activate PARs and lead to COX-2 expression
which might implicate in the vascular inﬂammatory responses.
Thrombin activates PARs which couple to multiple signaling
pathways and regulate diverse cellular functions. PARs can couple to
various G proteins such as Gq and Gi [9,10]. Activation of thrombin/
PARs system has been shown to trigger hydrolysis of phosphoinositide
(PI) and inhibition of adenylyl cyclase via distinct G proteins in platelet
and CCL-39 ﬁbroblasts, including Gq-like and Gi-like proteins,
respectively [13,17]. Several lines of evidence demonstrate that
mitogen activated protein kinases (MAPKs) could be activated by the
activation of Gq and Gi protein-coupled receptors via different signal
pathways. The principal mechanism underlying activation by throm-
bin is mediated through PAR-1 coupling Gq proteins, resulting in
activation of phospholipase C (PLC)-β, PI hydrolysis, and formation of
inositol trisphosphate (IP3) and diacylglycerol, leading to Ca2+ increase
and protein kinase C (PKC) activation [13]. MAPKs activation by
thrombin has been shown to modulate various cellular responses
including cell proliferation in various cell types [18]. Moreover, it has
been shown that signaling through MAPKs, extracellular signal-
regulated protein kinase 1/2 (ERK1/2) especially, in response to
GPCR agonists can be mediated through transactivation of the
epidermal growth factor receptor (EGFR) [19]. The transactivation of
EGFR by GPCRs mediated by activation of non-receptor tyrosine
kinases such as Src family or release of heparin-binding EGF-like
growth factor (HB-EGF) has been demonstrated in various cell types
[20]. Thrombin has also been shown to share this transactivation of
EGFR in various cell systems including astrocytes and SMCs, leading to
MAPK activation and then regulating cell proliferation and migration,
respectively [21,22]. Our previous report also demonstrates that in
human and canine tracheal SMCs, thrombin-mediated MAPK activa-
tion is modulated through a pertussis toxin (PTX)-sensitive G protein,
PI-PLC, Ca2+, PKC, tyrosine kinases, and PI3-kinase cascades associated
with cell proliferation [23,24]. More recently, we have shown that
several GPCR agonists (e.g. sphingosine 1-phosphate and bradykinin)
stimulate ERK1/2 phosphorylation associated with COX-2 expression
in rat VSMCs and astrocytes [25,26]. In addition, we have also
demonstrated that bradykinin stimulates ERK1/2 activation and cell
proliferation via Src family kinases and EGFR transactivation in VSMCs
[27]. However, the mechanisms underlying thrombin-induced MAPKs
activation linked to COX-2 expression and PGE2 production are not
completely deﬁned in VSMCs.
In this study, we investigated the effect of thrombin on expression
of COX-2 in rat primary culture VSMCs. These ﬁndings indicated that
thrombin induced COX-2 expression at the transcriptional and
translational levels, which were mediated through coupling to both
PTX-sensitive Gi and Gq protein PAR, activation of PKC(δ)/c-Src-
dependent MMPs and EGFR transactivation, ERK1/2, and NF-κB/AP-1
signaling pathways in VSMCs. These results provide new insights into
the mechanisms of thrombin action which may be therapeutic value
in vascular diseases.2. Materials and methods
2.1. Materials
Dulbecco's modiﬁed Eagle's medium (DMEM), Lipofectamine Plus reagent, and
fetal bovine serum (FBS) were purchased from Invitrogen (Carlsbad, CA). Hybond C
membrane and ECL Western blotting detection system were from GE HealthCare
(Buckinghamshire, UK). Anti-ERK1, PKC-δ, and c-Src antibodies were from Santa Cruz
(Santa Cruz, CA). PhosphoPlus ERK1/2 antibody kit was from New England Biolabs
(Beverly, MA). PhosphoPlus EGFR (Tyr845, Tyr992, Tyr1068, or Tyr1173), PhosphoPlus PKC-δ
and PhosphoPlus c-Src antibody kits were from Cell Signaling (Beverly, MA, USA). Anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was from Biogenesis
(New Fields, UK). Anti-COX-2 monoclonal antibody was from BD Transduction
Laboratories (San Diego, CA, USA). Thrombin, PPACK, pertussis toxin, GP antagonist-2,
GP antagonist-2A, GF109203X, rottlerin, U0126, GM6001, AG1478, PP1, curcumin,
tanshinone IIA, and helenalin were from Biomol (Plymouth Meetings, PA). Bicincho-
ninic acid (BCA) protein assay kit was from Pierce (Rockford, IL). Enzymes, CRM197, and
other chemicals were from Sigma (St. Louis, MO).
2.2. Rat aortic vascular smooth muscle cells (VSMCs) culture
VSMCs were isolated from Sprague–Dawley rat. Aortic strips were cut into small
pieces and placed in 6-well culture plates. These explants were grown in DMEM
containing 10% (v/v) FBS, 2 mM glutamine, nonessential amino acid and antibiotics
(100 U/ml penicillin G, 100 μg/ml streptomycin, and 250 ng/ml fungizone) at 37 °C in a
humidiﬁed 5% CO2 atmosphere. When the cultures reached conﬂuence, cells were
treated with 0.05% (w/v) trypsin/0.53 mM EDTA for 5 min at 37 °C. The cells were
counted and dilutedwith DMEMwith 10% FBS to a ﬁnal concentration of 2×104 cells/ml.
The cellswere platedonto (1ml/well) 12-well culture plates and (10ml/dish) 10 cm-dishes
for Western blotting and RT-PCR analyses, respectively. The medium was changed after
24 h and then every 3 days. VSMCs were identiﬁed by their characteristic “hill and valley”
growthpattern, theabsence of factorVIII antigenand thepresenceof SMC-speciﬁcα-actin.
2.3. Total RNA extraction and RT-PCR analysis
In accordance with the previous study, total RNA was extracted from VSMCs [25].
The cDNA obtained from 0.5 μg total RNAwas used as a template for PCR ampliﬁcation.
Oligonucleotide primers were designed based on Genbank entries for rat PAR-1 and
PAR-2 [28], COX-2, and β-actin. The following primers were used for ampliﬁcation
reaction: for COX-2, forward primer 5′-TGGTGCCGGGTCTGATGATG-3′; reverse primer
5′-GCAATGCGGTTCTGATACTG-3′; for β-actin, forward primer 5′-GAACCCTAAGGC-
CAACCGTG-3′; reverse primer 5′-TGGCATAGAGGTCTTTACGG-3′. The ampliﬁcation
was performed in 30 cycles at 55 °C, 30 s; 72 °C, 1 min; 94 °C, 30 s. PCR fragments
were analyzed on 2% agarose 1X TAE gel containing ethidium bromide and their size
was compared to a molecular weight marker. Ampliﬁcation of β-actin, a relatively
invariant internal reference RNA, was performed in parallel, and cDNA amounts were
standardized to equivalent β-actin mRNA levels. These primer sets speciﬁcally
recognize only the genes of interest as indicated by ampliﬁcation of a single band of
the expected size (253 bp for COX-2 and 514 bp for β-actin) and direct sequence analysis
of the PCR product.
2.4. Preparation of cell extracts and Western blotting analysis
Cells were plated on 12-well culture plates and made quiescent at conﬂuence by
incubation in serum-free DMEM for 24 h. Growth-arrested VSMCs were incubated with
or without thrombin at 37 °C for various times. The cell lysates were collected and the
protein concentration was determined by the BCA reagents according to the
instructions of the manufacturer. Samples from these cell lysates (30 μg protein)
were denatured and subjected to SDS-PAGE using a 10% (w/v) running gel. The
phosphorylation of ERK1/2, PKC-δ, c-Src, EGFR and expression of COX-2 were identiﬁed
and quantiﬁed by Western blotting analysis using an anti-phospho-ERK1/2, phospho-
PKC-δ, phospho-c-Src and phospho-EGFR, or COX-2 antibody according to our previous
studies [4,27]. Brieﬂy, membranes were then incubated overnight at 4 °C with anti-
phospho-PKC-δ, anti-phospho-c-Src or anti-phospho-ERK1/2 polyclonal antibody used
at a dilution of 1:1000 in TTBS. Membranes werewashed with TTBS four times for 5min
each, incubated with a 1:2000 dilution of anti-rabbit horseradish peroxidase antibody
for 1 h. Following each incubation, the membrane was washed extensively with TTBS.
The immunoreactive bands detected by ECL reagents were developed by Hyperﬁlm-
ECL.
2.5. Plasmids and transfection
The plasmids encoding DN-PKC-δ and DN-ERK (dominant negative mutants of PKC-δ
and ERK1) were kindly provided by Dr. P. Parker (Cancer Research Center UK, London,
UK) and Dr. K.L. Guan (Department of Biological Chemistry, University of Michigan),
respectively. The plasmid encoding short hairpin RNA of ERK1 (ERK shRNA) was kindly
provided by Dr. C.P. Tseng (Department of Medical Biotechnology and Laboratory
Science, University of Chang Gung, Tao-Yuan, Taiwan). All plasmids were prepared by
using QIAGEN plasmid DNA preparation kits. VSMCs were plated at 3×105 cells/ml
(2 ml/well) in 6-well culture plates for 24 h, reaching about 80% conﬂuence. Cells were
washed once with PBS and serum-free DMEM, and 0.8 ml of serum-free OPTI-MEM I
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prepared according to the instructions of the manufacturer. The amount of transfected
plasmid was kept constant (2 μg of DN-PKC-δ or DN-ERK for each well). The DNA PLUS-
Lipofectamine reagent complex (0.2 ml) was added to each well, incubated at 37 °C for
4 h, and then 1 ml of OPTI-MEM I medium containing 20% FBS added and further
incubated for 20 h. After 24 h of transfection, the cells were washed twice with PBS and
maintained in DMEM containing 10% FBS for 24 h. Cells were then washed once with
PBS and incubated with serum-free DMEM for 24 h before treatment with thrombin.
2.6. Transient transfection and reporter assays
The COX-2 promoter construct pGS459 (−459 to +9 bp)-luciferase reporter construct
wasagenerous gift fromDr. L.-H.Wang (Universityof Texas,Houston, TX). Theplasmidwas
preparedbyusingQIAGENplasmidDNApreparation kits and transfected intoVSMCsusing
the Lipofectamine reagent according to the instructions of the manufacturer. To assess
promoter activity, cells were collected and disrupted by sonication in lysis buffer (25 mM
Tris-phosphate, pH 7.8, 2 mM EDTA, 1% Triton X-100, and 10% glycerol). After
centrifugation, aliquots of the supernatants were tested for luciferase activity using the
luciferase assay system (Promega, Madison, WI) according to the manufacturer's
instructions. Fireﬂy luciferase activities were standardized to β-galactosidase activity.
2.7. Measurement of PGE2 and PGI2 levels
The cells were seeded in 12-well plates and grown to conﬂuence. Cells were washed
with PBS and incubated in serum-free DMEM/F-12 medium for 24 h, then treated with
thrombin for various times. The culture supernatant was collected to measure PGE2 and
PGI2 concentration using a monoclonal antibody in an EIA kit as speciﬁed by the manu-
facturer (Cayman Chemical).
2.8. MMP gelatin zymography
After thrombin (1 U/ml) treatment, the culture medium was collected and mixed
with equal amounts of non-reduced sample buffer and electrophoresed on 10% SDS-Fig. 1. Thrombin induces COX-2 expression and PGE2 synthesis in VSMCs. (A) Time- and (B) c
with various concentrations of thrombin for the indicated times. Thewhole cell lysates (A and
monoclonal antibody. Membranes were stripped and re-probed with an anti-GAPDH antibod
were treated with 1 U/ml thrombin for various times. The total RNAwas analyzed by RT-PCR
PGE2 and PGI2 synthesis, cells were treatedwith thrombin (1 U/ml) for various times. The con
Data are expressed as mean±SEM of three independent experiments. ⁎Pb0.05; #Pb0.01, as
individual experiments.PAGE containing 1 mg/ml gelatin as a protease substrate according to our previous
studies [29]. Gelatinolytic activity was manifested as horizontal white bands on a blue
background.
2.9. Analysis of data
Concentration-effect curves were ﬁtted and EC50 values were estimated using
GraphPad Prism Program (GraphPad, San Diego, CA, USA). Quantitative data were
analyzed using ANOVA followed by Tukey's honestly signiﬁcant difference tests
between individual groups. Data were expressed as mean±SEM. A value of Pb0.05 was
considered signiﬁcant.
3. Results
3.1. Thrombin induces COX-2 expression and PGE2 release
To determine the effect of thrombin on the COX-2 protein and
mRNA expression, VSMCs were treated with 1 U/ml thrombin for the
indicated times. Thrombin induced COX-2 protein expression in a
time-dependent manner, revealed by Western blot (Fig. 1A). There
was a signiﬁcant increase being observed within 2 h and reached a
maximal response within 24 h. The induction response of thrombin
was in a concentration-dependent manner and there was a signiﬁcant
increase from 0.01 U/ml of thrombin and a maximal response with
10 U/ml thrombin (Fig.1B). The EC50 value of thrombin-induced COX-2
expression was approximately 1.8 U/ml and 1 U/ml was used for the
remaining experiments. The blot was stripped and re-probed with an
anti-GAPDH antibody to demonstrate equivalent amount of GAPDH
expression. To further examine whether the effect of thrombin ononcentration-dependence of thrombin-induced COX-2 expression. Cells were incubated
B)were subjected to SDS-PAGE andWestern blot using an antiserum reactivewith COX-2
y as a control. (C) Time dependence of thrombin-induced COX-2 mRNA expression. Cells
as described under Materials and methods. (D) Time dependence of thrombin-induced
dition mediawere collected tomeasure PGE2 and PGI2 (insert panel) level using EIA kits.
compared with the cells exposed to vehicle alone. The ﬁgure represents one of three
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COX-2 mRNA was determined by RT-PCR. As shown in Fig. 1C,
thrombin (1 U/ml) induced COX-2 mRNA expression in a time-
dependent manner. There was a signiﬁcant increase in COX-2 mRNA
expression within 0.5 h, reached a maximal response within 4 h, and
sustained up to 6 h, whereas there was no effect on COX-1 mRNA level
(data not shown). In addition, the expression of β-actin mRNA as an
internal control was not changed (Fig. 1C).
To determine whether up-regulation of COX-2 led to PGE2
biosynthesis, we determined PGE2 level using an EIA. Thrombin
(1 U/ml) stimulated PGE2 release in a time-dependent manner in
VSMCs (Fig.1D). A signiﬁcant PGE2 generationwas detected within 4 h
(Pb0.05, n=3, compared with the basal level), peaked up within 16 h,
and declined but still signiﬁcant within 24 h. Moreover, to determine
whether other PGs such as PGI2 can be induced by thrombin in VSMCs,
PGI2 level was indirectly estimated by measuring its stable metabolite
PGF1α using an EIA. We found that thrombin also induced PGI2
release in a time-dependent manner (Fig. 1D, insert panel). A
signiﬁcant PGI2 generation was detected within 2–6 h. These results
suggested that thrombin induced COX-2 expression through increas-
ing mRNA and protein levels, and subsequent PGE2 and PGI2 release.
3.2. Thrombin induces COX-2 expression via a PTX-sensitive Gi and Gq
protein-couple receptor
To determine whether thrombin-induced COX-2 expression
mediated through thrombin proteolytic activity, a selective thrombin
inhibitor PPACK was used. Pretreatment with PPACK signiﬁcantly
inhibited thrombin-induced COX-2 protein expression in a concentra-
tion-dependent manner (Fig. 2A). To further conﬁrm whether VSMCs
expressed PARs, the presence of PARs mRNA in VSMCs was analyzed
by RT-PCR. As shown in Fig. 2B, PAR-1 mRNA was signiﬁcantly
presented in VSMCs, whereas therewas only little expression of PAR-2
in these cells. PAR-1 has been shown to be a pleiotropic GPCR forFig. 2. Involvement of thrombin proteolytic activity, Gq protein, and PTX-sensitive Gi prote
induced COX-2 protein expression, cells were pretreated with PPACK for 1 h and incubated
primary culture rat VSMCs. Lane 1: PAR-1 primers and VSMC RNA. Lane 2: PAR-2 primers
thrombin-induced COX-2 expression and PGE2 synthesis, cells were pretreated with pertussi
and then exposed to thrombin for 6 h. COX-2 protein and PGE2 synthesis were analyzed
independent experiments. #Pb0.01, as compared with the respective values of cells stimulathrombin which is capable of activating G proteins including Gi, Gq,
and G12/13 [11,30]. To further determine which kind of GTP binding
proteins was involved in thrombin-induced COX-2 expression, a Gi
protein inhibitor pertussis toxin (PTX), Gi antagonist GP antagonist-2
(GPAnt2), and Gq protein antagonist (GPAnt2A) were used. Pretreat-
ment of VSMCs with PTX, GPAnt2 or GPAnt2A and then exposure to
1 U/ml thrombin for 6 h signiﬁcantly attenuated the thrombin-
induced COX-2 expression and PGE2 release in a concentration-
dependent manner (Fig. 2C and D), implicating that thrombin induces
COX-2 expression and PGE2 release through a GPCR (i.e. PAR-1)
coupling to a PTX-sensitive Gi protein and Gq protein in VSMCs.
3.3. PKC(δ) mediates thrombin-induced COX-2 expression and PGE2
release
PKC has been shown to play an important role in the cellular
functions modulated by several stimuli such as thrombin [31]. To test
the possibility of involvement of PKC activation in thrombin-induced
COX-2 expression, a non-selective PKC inhibitor GF109203X was used.
Pretreatment with GF109203X signiﬁcantly attenuated thrombin-
induced COX-2 expression in a concentration-dependent manner
(Fig. 3A). PKC-α, PKC-β, PKC-δ, and PKC-ζ have been shown to be
expressed in SMC [31,32]. PKC-δ is the most abundantly expressed in
rat aortic SMCs [33]. Thus, a selective PKC-δ inhibitor rottlerin was
used. Pretreatment with rottlerin signiﬁcantly inhibited thrombin-
induced response in a concentration-dependent manner (Fig. 3B), sug-
gesting that PKC-δ plays a potential role in thrombin-induced COX-2
expression in VSMCs. To further ensure the role of PKC-δ in this
response, transfection of cells with a dominant negativemutant of PKC-
δ (DN-PKC-δ) and then stimulation with thrombin (1 U/ml) for 6 h
attenuated thrombin-induced COX-2 expression (Fig. 3C). Furthermore,
wedeterminedwhether PKC-δ translocation, an indexof PKC activation,
was involved in thrombin-induced COX-2 expression in VSMCs
analyzed by Western blotting. As shown in Fig. 3D, PKC-δ was rapidlyin in thrombin-induced COX-2 expression in VSMCs. (A) Effect of PPACK on thrombin-
with thrombin for 6 h. (B) RT-PCR analysis of protease-activated receptor expression in
and VSMC RNA. (C and D) Effects of pertussis toxin, Gi and Gq protein antagonists on
s toxin (PTX), Gi antagonist (GPAnt2) or Gq antagonist (GPAnt2A) for the indicated times
as described in “Materials and methods”. Data are expressed as mean±SEM of three
ted with thrombin alone. The ﬁgure represents one of three individual experiments.
1567H.-L. Hsieh et al. / Biochimica et Biophysica Acta 1783 (2008) 1563–1575translocated to plasma membrane as early as 1 min upon thrombin
stimulation, sustained over 5 min, and then declined to the basal level
within 10 min. Moreover, pretreatment with 1 μM rottlerin signiﬁ-
cantly blocked BK-stimulated PKC-δ translocation in VSMCs (Fig. 3D,
last lane), implicating that thrombin can induce PKC-δ translocation in
VSMCs.
Moreover, the RT-PCR data showed that pretreatment with PKC
inhibitors GF109203X (3 μM) or rottlerin (1 μM) also signiﬁcantly
inhibited thrombin-induced COX-2 mRNA expression (Fig. 3E),
suggesting that PKC-δ participates in regulation of thrombin-induced
COX-2 expression at transcriptional level. To further determine the
involvement of PKC(δ) in PGE2 release stimulated by thrombin,
pretreatment of cells with GF109203X (3 μM) or rottlerin (1 μM) for
1 h, and then exposure to 1 U/ml thrombin for 6 h inhibited thrombin-
induced PGE2 release, respectively (Fig. 3F). These data indicate that
PKCs, especially PKC-δ, are required for thrombin-induced COX-2
expression and PGE2 release in VSMCs.
3.4. Thrombin-induced COX-2 expression and PGE2 release is mediated
through ERK1/2 phosphorylation
Previous reports have demonstrated that stimulation of many
GPCRs such as PAR-1 leads to a rapid activation of the ERK signaling
pathway [34]. Thrombin has also been shown to regulate the activities
of ERK1/2 in various cell types [24,34]. Recently, our report has shown
that sphingosine 1-phosphate induces COX-2 expression via an ERK-
dependent pathway in VSMCs [25]. To determinewhether thrombin-!
DEL id="del311" orig="- ">induced COX-2 expression and PGE2 release
wasmediated through ERK1/2 activation, pretreatment of VSMCswithFig. 3. Effects of PKC inhibitors on thrombin-induced COX-2 expression and PGE2 synthes
incubated with thrombin (1 U/ml) for 6 h. (C) The cells were transfected with plasmids enco
then stimulated with 1 U/ml thrombin for 6 h. (D) The translocation of PKC-δ was determin
times, or pretreated with 1 μM rottlerin (Rott) for 1 h and then stimulated with thrombin for
rottlerin (1 μM) for 1 h and then stimulated with thrombin (1 U/ml) for 4 h. The total RNA w
cells were pretreatedwith GF109203X (3 μM) or rottlerin (1 μM) for 1 h and then stimulatedw
using an EIA kit. The whole cell lysates (A–D) were subjected to SDS-PAGE and Western blot
experiments. ⁎Pb0.05; #Pb0.01, as compared with the respective values of cells stimulated wa selective MEK1/2 inhibitor U0126 for 1 h and then stimulation with
1 U/ml thrombin for 6 h caused an attenuation of COX-2 protein
expression in a concentration-dependent manner (Fig. 4A). Moreover,
pretreatment of VSMCs with 10 μM U0126 also attenuated the
thrombin-induced COX-2 mRNA expression (Fig. 4B). To further
determine the involvement of ERK1/2 in thrombin-induced PGE2
release in VSMCs, pretreatment of cells with U0126 for 1 h and then
stimulation with 1 U/ml thrombin for 6 h attenuated thrombin-
induced PGE2 release in a concentration-dependent manner (Fig. 4C).
These data demonstrate that ERK1/2 is essential for thrombin-induced
COX-2 expression and PGE2 release in VSMCs.
To determine whether thrombin-induced COX-2 expression is
mediated through phosphorylation of ERK1/2, activation of these
kinases was assayed using an antibody speciﬁc for the phosphory-
lated, active forms of ERK1/2 by Western blot. As shown in Fig. 4D,
thrombin (1 U/ml) stimulated a time-dependent phosphorylation of
MEK1/2 (the upstream kinases of ERK) and ERK1/2 in VSMCs. The
maximal response was obtained within 3 min (Pb0.01, as compared
with the basal level) and then declined within 10 min. There was no
change at the level of endogenous ERK as determined using an anti-
ERK2 antibody (data not shown). It has been shown that ERK1/2 is
activated by the kinases MEK1/2. Therefore, the relationship between
ERK1/2 and COX-2 induction was investigated using a MEK1/2
inhibitor U0126. Pretreatment of VSMCs with U0126 signiﬁcantly
decreased thrombin-stimulated ERK1/2 phosphorylation in a concen-
tration-dependent manner (Fig. 4E). The phosphorylation of ERK1/2
by thrombin was almost completely inhibited when cells were
preincubated with 10 μM U0126. To further conﬁrm whether ERK1/2
phosphorylation is directly involved in thrombin-induced COX-2is in VSMCs. Cells were treated with (A) GF109203X or (B) rottlerin for 1 h and then
ding dominant negative PKC-δ mutant (DN-PKCδ) or pcDNA3 (an empty plasmid), and
ed by Western blotting. Cells were stimulated with 1 U/ml thrombin for the indicated
1 min. (E) For COX-2 mRNA expression, cells were pretreated with GF109203X (3 μM) or
as analyzed by RT-PCR as described in “Materials and methods”. (F) For PGE2 synthesis,
ith thrombin (1 U/ml) for 6 h. The conditionmediawere collected tomeasure PGE2 levels
analysis as described in Fig. 1. Data are expressed as mean±SEM of three independent
ith thrombin alone. The ﬁgure represents one of three individual experiments.
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mutant (DN-ERK) or ERK1 shRNA signiﬁcantly inhibited thrombin-
induced COX-2 expression (Fig. 4F and G). The endogenous ERK1
protein was knocked down by transfection with ERK1 shRNA for 24 h,
whereas a housekeeping protein GAPDH was not affected. These
results suggested a link between activation of MEK-ERK cascade and
up-regulation of COX-2 in VSMCs.
3.5. Thrombin-induced COX-2 expression is mediated through a
PKC-δ-dependent c-Src phosphorylation
Several studies have shown that the Gi protein βγ complex activates
non-receptor tyrosine (Tyr) kinases such as Src,whichmight affectmany
cellular functions [9,35]. We have determined that Tyr kinases may be
involved in thrombin-induced COX-2 expression using a Tyr kinase
inhibitor genistein (data not shown). To investigate whether a non-
receptor Tyr kinase c-Src was also involved in thrombin-induced
responses, a selective c-Src inhibitor PP1 was used. As shown inFig. 4. Involvement of ERK1/2 in thrombin-induced COX-2 expression in VSMCs. (A) For COX
1 U/ml thrombin for 6 h. (B) For COX-2mRNA expression, the cells were treated with 1 U/ml t
described under Materials and methods. (C) For PGE2 synthesis, cells were pretreated with U
were collected tomeasure PGE2 levels using an EIA kit. (D) Time dependence of thrombin-stim
times. (E) Dose-dependent inhibition of thrombin-stimulated ERK1/2 phosphorylation by U0
for 3min. (F) The cells were transfectedwith plasmids encoding dominant negative ERKmuta
thrombin for 6 h. (G) The VSMCs were transfected with ERK1 shRNA plasmid encoding ERK1
Whole cell lysates were subjected to Western blot using an anti-phospho-MEK1/2 (D), an
expressed as mean±SEM of four independent experiments. ⁎Pb0.05; #Pb0.01, as compared w
G) alone. The ﬁgure represents one of three individual experiments.Fig. 5A, pretreatmentwith PP1 signiﬁcantly inhibited thrombin-induced
COX-2 expression in a concentration-dependentmanner (Pb0.01, n=3).
Furthermore, to conﬁrm whether c-Src activation is involved in
thrombin-induced COX-2 expression, transfection with a dominant
negative c-Src mutant (DN-Src) signiﬁcantly attenuated thrombin-
induced COX-2 expression (Fig. 5B). To demonstratewhether thrombin-
induced COX-2 expression is mediated through c-Src activation, c-Src
phosphorylation was determined using an antibody speciﬁc for the
phosphorylated, active form of c-Src. As shown in Fig. 5C, thrombin
stimulated phosphorylation of c-Src in a time-dependent manner. A
maximal responsewas obtainedwithin 1min and then declined close to
the basal level within 5 min. Pretreatment of VSMCs with PP1 (1 μM)
almost completely inhibited thrombin-stimulated c-Src phosphoryla-
tionwithin 5min in VSMCs (Fig. 5C). To determinewhether activation of
c-Src mediated through PKC-δ during thrombin-induced response, a
PKC-δ inhibitor rottlerinwas used. As shown in Fig. 5D, pretreatment of
VSMCswith rottlerin (1 μM)signiﬁcantly inhibited thrombin-stimulated
c-Src phosphorylation, indicating that PKC-δ may be an upstream-2 protein expression, the cells were pretreated with U0126 for 1 h and incubated with
hrombin for 4 h in the presence of 1 μMU0126. The total RNAwas analyzed by RT-PCR as
0126 for 1 h and then stimulated with thrombin (1 U/ml) for 6 h. The condition media
ulated ERK1/2 phosphorylation, cells were incubated with 1 U/ml thrombin for various
126, cells were pretreated with U0126 for 1 h and then were stimulated with thrombin
nt (DN-ERK) or pcDNA3 (an empty plasmid), and then stimulatedwith vehicle or 1 U/ml
shRNA or pTOPO-U6 (as a control), and then stimulated with 1 U/ml thrombin for 6 h.
ti-phospho-ERK1/2 antibody (D and E), or anti-COX-2 antibody (A, F and G). Data are
ith the respective values of cells stimulated with vehicle (D) or thrombin (A, B, C, F and
Fig. 5. Involvement of c-Src in thrombin-induced COX-2 expression in VSMCs. (A) For COX-2 protein expression, cells were pretreatedwith PP1 for 1 h and then incubatedwith 1 U/ml
thrombin for 6 h. (B) The cells were transfected with plasmids encoding dominant negative Src mutant (DN-Src) or pcDNA3 (an empty plasmid), and then stimulated with vehicle or
1 U/ml thrombin for 6 h. (C) Time dependence of thrombin-stimulated c-Src phosphorylation, cells were pretreated with 1 μM PP1 for 1 h and then incubated with 1 U/ml thrombin
for various times. (D) Thrombin induced c-Src phosphorylation via PKC-δ, cells were pretreated with 1 μM rottlerin for 1 h and then stimulated with thrombin for the indicated times.
The cell lysates were subjected to SDS-PAGE and the expression of COX-2 (A and B) or the phosphorylation of c-Src (C and D) as described in “Materials and methods”. (E) For PGE2
synthesis, cells were pretreated with PP1 for 1 h and then stimulated with thrombin (1 U/ml) for 6 h. The condition mediawere collected tomeasure PGE2 concentration using an EIA
kit. Data are expressed as mean±SEM of four independent experiments. ⁎Pb0.05; #Pb0.01, as compared with the respective values of cells stimulated with thrombin (A, B, and E)
alone. The ﬁgure represents one of three individual experiments.
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PGE2 release was signiﬁcantly attenuated by pretreatment of VSMCs
with PP1 (Fig. 5E). These results suggest that thrombin-induced COX-2
expression and PGE2 release may be mediated through a PKC-δ-
dependent c-Src phosphorylation in VSMCs.Fig. 6. Involvement of transactivation of EGFR in thrombin-induced COX-2 expression in VSM
incubated with 1 U/ml thrombin for 6 h. (B) Time dependence of thrombin-stimulated EGFR
(C) For EGFR Tyr1173 phosphorylation, the cells were pretreated with AG1478 for 1 h and then
and the expression of COX-2 and Tyr1173 phosphorylation of EGFR were determined as de
pretreated with AG1478 for 1 h and the incubated with 1 U/ml thrombin for 4 h. The total RN
1 h and then stimulated with thrombin (1 U/ml) for 6 h. The condition media were collect
independent experiments. ⁎Pb0.05; #Pb0.01, as compared with the respective values of cells
of three individual experiments.3.6. Thrombin-induced COX-2 expression is mediated through
transactivation of EGFR
It has been demonstrated that several GPCR agonists activate non-
receptor tyrosine kinases such as Src family, which might lead toCs. (A) For COX-2 protein expression, cells were pretreated with AG1478 for 1 h and then
Tyr1173 phosphorylation, cells were incubated with 1 U/ml thrombin for various times.
incubated with 1 U/ml thrombin for 1 min. The cell lysates were subjected to SDS-PAGE
scribed in “Materials and methods”. (D) For COX-2 mRNA expression, the cells were
Awas analyzed by RT-PCR. (E) For PGE2 synthesis, cells were pretreated with AG1478 for
ed to measure PGE2 levels using an EIA kit. Data are expressed as mean±SEM of four
stimulated with vehicle (B) or thrombin (A, C, D and E) alone. The ﬁgure represents one
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[9,36]. The EGFR has been shown to be activated by thrombin in
various cell types [35]. Thus, to determine whether transactivation of
EGFR was involved in thrombin-induced COX-2 expression, a selective
EGFR inhibitor AG1478 was used. As shown in Fig. 6A, pretreatment
of VSMCs with AG1478 signiﬁcantly attenuated thrombin-induced
COX-2 expression in a concentration-dependent manner (Pb0.01,
n=3). To further determinewhether thrombin can induce activation of
EGFR, because tyrosine phosphorylation of Tyr1173 is essential for
EGFR activation, we used anti-phospho-(Tyr1173)-EGFR antibody to
determine EGFR activation in this study. Thrombin (1 U/ml)
stimulated a time-dependent Tyr1173 phosphorylation of EGFR in
VSMCs (Fig. 6B). A maximal response was obtained within 1 min
(Pb0.01, as compared with the basal level), then slightly declined
within 3 min and returned to the basal level within 10 min.
Pretreatment of VSMCs with AG1478 signiﬁcantly inhibited throm-
bin-stimulated EGFR phosphorylation in a concentration-dependent
manner (Fig. 6C). In addition, thrombin-induced COX-2 mRNA
expression and PGE2 release were also signiﬁcantly inhibited by
pretreatment of VSMCs with AG1478 (Figs. 6D and 7E). These results
suggested that thrombin-induced COX-2 up-regulation and PGE2
release were mediated through the transactivation of EGFR in VSMCs.
3.7. Thrombin transactivates EGFR via PKC-δ/c-Src-dependent MMPs
activation leading to ERK1/2 phosphorylation
Signaling through ERK1/2 in response to various GPCR agonists can
be mediated through transactivation of the EGFR [19,21]. Thrombin has
been shown to transactivate the EGFR via HB-EGF in various cell types
such as rat aortic SMCs [22]. Our above data have demonstrated that
PKC-δ, c-Src and EGFRwere necessary for the COX-2 expression induced
by thrombin in VSMCs. Therefore, it would be important to differentiateFig. 7. Roles of PKC-δ, c-Src, and MMPs/HB-EGF in thrombin-induced transactivation of EGFR
and PP1 (1 μM), (B) GM6001 (1 μM) or CRM197 (10 μg/ml), and (C) MMP2/9 inhibitor (3 μM)
activation, cells were pretreated with GM6001 (GM,1 μM), MMP2/9 inhibitor (2/9i, 3 μM), GF
1 U/ml thrombin for 1min. The conditionmediawere analyzed by gelatin zymography. aMMP
GM6001 (GM, 1 μM), MMP2/9 inhibitor (2/9i, 3 μM), CRM197 (CRM, 10 μg/ml) or AG1478 (A
pretreated with GPAnt2 (10 μM) or GPAnt2A (10 μM) for 1 h and then stimulated with 1 U/m
an (A) anti-phospho-(Tyr845, Tyr992 or Tyr1068) EGFR, (A–C, and F) anti-phospho-(Tyr1173) EG
The ﬁgure represents one of three similar experiments.whether PKC-δ and c-Src are associated with EGFR transactivation and
linking to ERK1/2 activation. To examine this possibility, the tyrosine
phosphorylations of EGFR, including Src-phosphorylated site (onTyr845)
[37] and autophosphorylation sites (Tyr992, Tyr1068, and Tyr1173) were
assessed following thrombin stimulation in the presence of inhibitors
for PKC-δ and c-Src, respectively. As shown in Fig. 7A, stimulation of
VSMCs with thrombin (1 U/ml) for indicated times increased EGFR
tyrosinephosphorylationonTyr845, Tyr992, Tyr1068, andTyr1173 thatwere
signiﬁcantly blocked by pretreatment with either PKC-δ inhibitor
rottlerin (1 μM) or c-Src inhibitor PP1 (1 μM), suggesting that both
PKC-δ and c-Src are essential for thrombin-stimulated EGFR transactiva-
tion in VSMCs. Moreover, matrix metalloproteinases (MMPs) and
proHB-EGF shedding have been shown in the transactivation of EGFR
by GPCRs such as LPA [36]. To examine whether thrombin-stimulated
EGFR transactivation is dependent on MMPs activation and HB-EGF
release, a broad-spectrumMMP inhibitorGM6001 andHB-EGF inhibitor
CRM197 were used. As shown in Fig. 7B, pretreatment of VSMCs with
GM6001 (1 μM) or CRM197 (10 μg/ml) signiﬁcantly blocked thrombin-
induced EGFR autophosphorylation on Tyr1173, as determined by
Western blotting, suggesting that MMPs and HB-EGF are involved in
thrombin-induced EGFR activation. Furthermore, the role of MMPs,
especially MMP-9, in EGFR transactivation by thrombin was further
veriﬁed with a selective MMP2/9 activity inhibitor MMP2/9i. As shown
in Fig. 7C, 3 μMMMP2/9i pretreatment signiﬁcantly inhibited thrombin-
stimulated Tyr1173 phosphorylation of EGFR. In the meanwhile, we also
demonstrated that thrombin truly inducedMMP-9 activation (aMMP-9)
within 1min by gelatin zymography (Fig. 7D), whichwas attenuated by
pretreatment of GM6001 (GM, 1 μM), MMP2/9 inhibitor (9/2i, 3 μM),
GF109203X (GF, 3 μM), rottlerin (Rott, 1 μM), and PP1 (1 μM),
respectively. These results suggest that MMPs (i.e. MMP-9) may be a
crucial mediator in thrombin-stimulated EGFR transactivation cascade
in VSMCs.and ERK1/2 phosphorylation in VSMCs. Cells were pretreated with (A) rottlerin (1 μM)
for 1 h and then stimulated with 1 U/ml thrombin for the indicated times. (D) For MMPs
109203X (GF, 3 μM), rottlerin (Rott, 1 μM) or PP1 (1 μM) for 1 h and then stimulated with
-9 (active formMMP-9). (E) Cells were pretreatedwith rottlerin (Rott,1 μM), PP1 (1 μM),
G, 1 μM) for 1 h and then stimulated with1 U/ml thrombin for 3 min. (F) VSMCs were
l thrombin for the indicated times. The cell lysates were subjected toWestern blot using
FR, (F) anti-phospho-PKC-δ, (F) anti-phospho-c-Src, or (E and F) anti-phospho-ERK1/2.
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required for ERK1/2 phosphorylation, pretreatment of VSMCswith the
inhibitors of PKC-δ (rottlerin, 3 μM), c-Src (PP1, 1 μM), pan-MMP
(GM6001, 1 μM), MMP2/9 (2/9i, 3 μM), HB-EGF (CRM197, 10 ng/ml), or
EGFR (AG1478, 1 μM) signiﬁcantly attenuated thrombin (1 U/ml, for
3 min)-stimulated ERK1/2 phosphorylation (Fig. 7E). These results
indicated that thrombin-induced COX-2 expression was mediated
through a sequential activation of PKC-δ/c-Src, MMPs (i.e. MMP2/9),
EGFR transactivation, and ERK1/2 in VSMCs. Moreover, we have found
that thrombin-induced COX-2 expression and PGE2 release through a
PTX-sensitive Gi protein- and Gq protein-coupled PAR receptors in
VSMCs (Fig. 2). To further conﬁrm a role of G protein including Gi and
Gq in regulation of the foregoing kinases, a Gi protein antagonist
(GPAnt2) and Gq protein antagonist (GPAnt2A) were used, respec-Fig. 8. Involvement of AP-1 and NF-κB in COX-2 expression induced by thrombin in VSMCs. Fo
for 1 h and then incubated with 1 U/ml thrombin for 6 h. The cell lysates were subjected to S
translocation of NF-κB stimulated by thrombin, VSMCs were pretreatedwith helenalin (1 μM)
fractions were analyzed by Western blotting as described in Materials and methods. (D)
were transfected with a promoter containing AP-1 (pAP1-Luc, left panel) or NF-κB bindin
β-galactosidase plasmid, and then incubatedwith thrombin (1 U/ml) for 6 h in the presence of
normalized to β-galactosidase activity. (E) For COX-2 mRNA expression, the cells were pretre
thrombin for 4 h. The total RNA was analyzed by RT-PCR. (F) For PGE2 synthesis, cells were
stimulatedwith thrombin (1 U/ml) for 6 h. The conditionmediawere collected tomeasure PGE
experiments. Data are expressed as mean±SEM of four independent experiments. ⁎Pb0.05; #
The ﬁgure represents one of three individual experiments.tively. As shown in Fig. 7F, pretreatment of VSMCs with GPAnt2A
signiﬁcantly attenuated thrombin-stimulated phosphorylation of
PKC-δ, c-Src, EGFR, and ERK1/2, indicating that Gq protein participates
in activation of PKC-δ, c-Src, EGFR, and ERK1/2 by thrombin. Contra-
riously, GPAnt2 pretreatment signiﬁcantly blocked phosphorylation of
c-Src, EGFR, and ERK1/2, but not PKC-δ, implicating that Gi protein
may be not involved in thrombin-mediated activation of PKC-δ in
VSMCs.
3.8. Thrombin up-regulates COX-2 expression via AP-1 and NF-κB
The COX-2 promoter has been shown to contain several binding
site for various transcription factors including AP-1 and NF-κB [38,39].
Several lines of evidence have also demonstrated that NF-κB and AP-1r COX-2 protein expression, the cells were pretreated with (A) curcumin or (B) helenalin
DS-PAGE and the expression of COX-2 was determined as described in Fig. 1. (C) Nuclear
for 1 h and then incubatedwith 1 U/ml thrombin for 10min. The nuclear and cytoplasm
Activities of the AP1-luciferase and κB-luciferase reporter constructs in VSMCs, cells
g sites promoter-luciferase reporter construct (pκB-Luc, right panel) together with a
curcumin (Curc,10 μM), helenalin (HLN,10 μM), or U0126 (10 μM). Luciferase activitywas
ated with curcumin (10 μM) or helenalin (10 μM) for 1 h and then incubated with 1 U/ml
pretreated with curcumin (1 and 10 μM) or helenalin (1 and 10 μM) for 1 h and then
2 concentration using an EIA kit. Data are expressed asmean±SEMof three independent
Pb0.01, as compared with the respective values of cells stimulated with thrombin alone.
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1-phosphate and BK to induce COX-2 expression [25,26]. To
investigate whether AP-1 and NF-κB were also involved in thrombin-
induced COX-2 expression in VSMCs, a selective AP-1 and NF-κB
inhibitor, curcumin [40] and helenalin [41], were used, respectively. As
shown in Fig. 8A and B, pretreatment of VSMCs with curcumin or
helenalin signiﬁcantly inhibited thrombin-induced COX-2 protein
expression in a concentration-dependent manner (Pb0.01, n=3). In
the meanwhile, we found that thrombin-increased translocation of
p65, a typical subunit of NF-κB, into nucleus (Fig. 8C) was almost
completely inhibited by pretreatment with helenalin (1 μM). Further-
more, to examine whether thrombin can induce AP-1 and NF-κB acti-
vation in VSMCs, the promoter reporter constructs containing AP-1 or
NF-κB binding site were used. The data showed that thrombin (1 U/ml,
for 6 h) induced AP1-luciferase activity increase was signiﬁcantly
reduced by pretreatment with curcumin (Curc, 10 μM) or U0126
(10 μM), respectively (Fig. 8D, left panel). Next, thrombin (1 U/ml, for
6 h)-induced NF-κB-luciferase activity increase was also signiﬁcantly
inhibited by pretreatment with helenalin (HLN, 1 μM) or U0126
(10 μM), respectively (Fig. 8D, right panel). Moreover, pretreatment
with curcumin or helenalin signiﬁcantly inhibited thrombin-induced
COX-2 mRNA expression and PGE2 release (Fig. 8E and F). These data
demonstrated that both AP-1 and NF-κB are crucial transcription
factors for thrombin-induced COX-2 expression and PGE2 release in
VSMCs.
3.9. Thrombin regulates COX-2 transcription activity
Furthermore, to determine whether thrombin regulated COX-2
expression at transcription level, VSMCswere transfectedwith a COX-2
promoter-luciferase reporter construct (pGS459-Luc) and then stimu-
lated with 1 U/ml thrombin for various times. As shown in Fig. 9 (inset
panel) activation of the COX-2 promoter by thrombin reached a peak
within 1 h and declined to the basal level within 4 h. Moreover,
previous reporters have indicated that the promoter of COX-2 contains
several binding sites for various transcription factors including AP-1
and NF-κB [38]. Thus, to further investigate whether AP-1 and NF-κB
are involved in thrombin-induced COX-2 expression, VSMCs were
transfected with pGS459-Luc, pretreated with curcumin and anotherFig. 9. Induction of the COX-2 promoter activity by thrombin in VSMCs. Time
dependence of thrombin-stimulated COX-2 promoter activity, cells were transfected
with a COX-2-luciferase plasmid (pGS459-Luc) containing COX-2 promoter region with
a β-galactosidase plasmid, and exposed to thrombin (1 U/ml) for indicated times (inset
panel). Cells cotransfected with pGS459-Luc and β-galactosidase plasmid were
pretreated with rottlerin (Rott, 1 μM), PP1 (1 μM), AG1478 (AG, 1 μM), U0126 (U0,
10 μM), curcumin (Curc, 10 μM), tanshinone IIA (TAS, 10 μM) or helenalin (HLN, 10 μM)
for 1 h and then stimulated with thrombin (1 U/ml) for 1 h. Promoter activities were
normalized to β-galactosidase activity. Data are expressed as mean±SEM of three
independent experiments. ⁎Pb0.05; #Pb0.01, as comparedwith the respective values of
cells stimulated with vehicle (inset panel) and thrombin alone.AP-1 inhibitor tanshinone IIA [42] or helenalin (1 μM) for 1 h, and then
stimulated with 1 U/ml thrombin for 1 h. As expected, pretreatment of
cells with curcumin (Curc), tanshinone IIA (TAS, 10 μM) or helenalin
(HLN) signiﬁcantly attenuated COX-2 promoter activation (Pb0.05,
n=3) in response to thrombin (Fig. 9). Moreover, the activity of the
COX-2 promoter stimulated by thrombin was also inhibited by
pretreatment with GF109203X (GF), PP1, AG1478 (AG), and U0126
(U0), respectively (Fig. 9). These results indicated that thrombin-
induced COX-2 expression is mediated through PKC-δ/c-Src-depen-
dent EGFR transactivation, ERK1/2, AP-1 and NF-κB pathways, and
subsequent regulated COX-2 gene transcription activity.
4. Discussion
Several lines of evidence have suggested that high levels of PGs,
synthesized by COX-2, are involved in mediating inﬂammatory
responses. The expression of COX-2 has been shown in several
inﬂammatory diseases and displays a wide range of biological activities
in different tissues, blood vessels in particular, including proliferation,
development, cancers, and inﬂammation [2,43]. Moreover, thrombin is
elevated in the region during vascular injuries and inﬂammation [7,15].
Thrombin has been shown to regulate the activities of COX-2 through
MAPKs in various cell types [16,44]. However, little is known about the
signaling mechanisms underlying thrombin-induced COX-2 expression
in VSMCs. In this study, we have applied Western blot analysis, RT-PCR,
selective pharmacological inhibitors, transfection with dominant nega-
tive mutants and shRNA, and promoter assay to investigate the
mechanisms by which thrombin induced COX-2 expression. Our results
demonstrated that thrombin-induced COX-2 expression and subse-
quent PGE2 and PGI2 synthesis in VSMCs aremediated through PKC-δ/c-
Src-dependent EGFR transactivation andMEK-ERK1/2 cascade linking to
AP-1 and NF-κB activation.
Several studies have reported that thrombin-induced diverse
biological effects are due to the unique proteolytic activation of GPCR
(PARs) family [10]. Thrombin activates PARs which can couple to
various G proteins such as Gq and Gi and leading to multiple signaling
pathways and regulate diverse cellular functions [9,13]. Moreover, the
PAR-1 has been shown to be expressed in various cell types including
smooth muscle cells [10]. Thus, we ﬁrst demonstrated that predomi-
nant PAR-1 is expressed in rat primary cultured VSMCs (Fig. 2A).
Thrombin-induced COX-2 expression was signiﬁcantly attenuated by
pretreatment with PPACK which is a selective thrombin proteolytic
activity inhibitor, indicating the requirement of thrombin proteolytic
activity for thrombin/PAR system-induced up-regulation of COX-2
(Fig. 2B). Many reports have shown that PAR-1 is a pleiotropic GPCR for
thrombin capable of activating G proteins including Gi, Gq, and G12/13
[11,30]. In this study, we further established that thrombin-induced
COX-2 expression and PGE2 release is mediated through a GPCR (i.e.
PAR-1) coupling to Gq protein and PTX-sensitive Gi protein in VSMCs,
consistent with our previous studies from human and canine tracheal
SMCs [23,24]. Moreover, according to previous reports [45,46] and our
results, thrombin-induced phosphorylation of c-Src might be directly
through Gi protein βγ complex (Fig. 7F), but at the same time Gq
protein-mediated phosphorylation of c-Src indirectly through PKC-δ in
VSMCs (Figs. 5D and 7F).
It has been reported that transactivation of RTK, EGFR especially,
mediates signaling in response to activation of many GPCRs such as
endothelin-1, LPA and bradykinin [19,21]. Moreover, thrombin, an
agonist of GPCR/PAR, has been found to transactivate EGFRs in diverse
cell types including HaCaT cells, astrocytes and smooth muscle cells
[21,22], and sequential linking to ERK1/2 activation [19,21]. Although
EGFR transactivation by GPCR agonists has been well studied, the
signaling mechanism by which thrombin-stimulated transactivation of
RTK such as EGFR in VSMCs has not been completely understood. Our
data showed that thrombin stimulated EGFR tyrosine phosphorylation
at Tyr1173 residue in a time-dependentmanner (Fig. 6B), and AG1478, an
Fig. 10. Schematic representation of signaling pathways involved in thrombin-induced
COX-2 expression and PGE2 release in VSMCs. Thrombin binding to its receptor (PAR-1)
which coupling to Gi and Gq proteins results in activation ofMEK-ERK1/2, AP-1, and NF-κB
through a transactivation of EGFR pathway. Thrombin stimulates activation of EGFR via
PKC-δ/c-Src-dependent activation of MMPs/HB-EGF. COX-2 transcription may be
regulated by both transcription factors AP-1 and NF-κB. These signaling pathways
might enforce each other and contribute to sustained activation of transcription factors
required for COX-2 gene expression. Finally, PGE2 and PGI2 were synthesized and released
in VSMCs.
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ylation (Fig. 7B) and subsequent COX-2 gene expression and PGE2
release stimulated by thrombin mediated through inhibition of EGFR
phosphorylation (Fig. 6C). These results are consistent with previous
reports indicating that BKmediates cell proliferation via transactivation
of EGFR in VSMCs [27] and thrombin stimulates cell migration in SMCs
[22]. In contrast,manystudies suggest that thrombin-inducedmitogenic
action in astrocytes or VSMCs occurs independently of EGF receptor
transactivation [34,47]. Thesedifferencesmaybedue to cell type speciﬁc
or different experimental conditions.
Several lines of evidence have shown that the Gi protein βγ
complex activates non-receptor tyrosine kinases such as Src, which
might transactivate growth factor receptors and modulate various
cellular functions [45,46]. Moreover, the involvement of Src in
transactivation of the EGFR by GPCRs has been reported in various
cell types [45,48]. Thus, in this study, we further investigated the
involvement of Src in thrombin-stimulated transactivation of EGFR
and activation of ERK. First, our data demonstrated that thrombin can
stimulate c-Src phosphorylation via both Gi and Gq protein-coupled
receptors (Figs. 5C and 7F), and next the PP1 signiﬁcantly inhibited
c-Src, EGFR (on Tyr845, Tyr992, Tyr1068, or Tyr1173) and ERK1/2
phosphorylation (Figs. 5C, 7A, and E) and subsequent COX-2 up-
regulation (Fig. 5A) and PGE2 release (Fig. 5D) induced by thrombin.
It is an interesting data for thrombin-mediated EGFR transactivation
through PKC-δ/c-Src-dependent activation of MMPs, especially
MMP-9, in COX-2 up-regulation pathway (Figs. 7B–E), consistent
with a recent report showing LPA-induced IL-8 secretion in HBEpCs
[36]. Moreover, we conﬁrmed these results by transfection of cells
with a dominant negative c-Src (DN-Src) that signiﬁcantly inhibited
induction of COX-2 expression by thrombin (Fig. 5B). In contrast,
AG1478 scarcely affected c-Src phosphorylation stimulated by
thrombin (data not shown). These results suggested that c-Src may
serve as an upstream component of EGFR by directly phosphorylated
EGFR on Tyr845 and indirectly activated MMPs/HB-EGF cascade in
regulating COX-2 expression and PGE2 release stimulated by
thrombin, consistent with previous studies that preincubation of
rat gastric mucosal epithelial cells with PP2 completely abrogated
PAR-1 agonists-induced MAPK activation and COX-2 expression [44].
In contrast, another report has implicated that Src probably acts as a
downstream of the EGFR for PAR-1-mediated ERK1/2 activation and
cell proliferation in colon cancer cells [35].
In addition, PKC may act as an upstream signaling molecule of the
EGFR transactivation [20,48]. Accordingly, pretreatment of VSMCs
with a pan-PKC inhibitor GF109203X or a selective PKC-δ inhibitor
rottlerin signiﬁcantly attenuated thrombin-stimulated responses. Our
results further demonstrated that thrombin-stimulated EGFR trans-
activation and ERK1/2 activation likely depended on PKCs, especially
PKC-δ (Fig. 7). Moreover, previous studies have shown that PKC-δ is
expressed on SMC [31,32], and it is the most abundantly expressed on
rat aortic SMCs [33]. Therefore, we further demonstrated that
thrombin stimulated PKC-δ translocation and phosphorylation indeed
(Figs. 3D and 7F), which was involved in thrombin-induced COX-2
mRNA and protein expression and PGE2 release in rat VSMCs (Fig. 3).
Moreover, we also demonstrated that thrombin stimulated phosphor-
ylation of PKC-δ via a Gq protein-coupled receptor, but not Gi (Fig. 7F)
leading to phosphorylation of c-Src in VSMCs (Fig. 5D). The role of
PKC-δ in induction of COX-2 protein was further conﬁrmed by
transfection with a dominant negative PKC-δ that attenuated COX-2
expression (Fig. 3D), consistent with our recent reports indicating that
BK-induced cPLA2 and COX-2 expression is mediated through a PKC-δ-
dependent pathway in brain astrocytes [25,26] and LPA-induced IL-8
secretion in HBEpCs [36].
It has beenwell established that inﬂammatory responses following
exposure to extracellular stimuli are highly dependent on activation of
AP-1 and NF-κB transcription factors, which play an important role in
regulation of several gene expression [49]. The 5′-ﬂanking region ofthe COX-2 promoter has been shown to contain several binding
sequences for various transcription factors including AP-1 and NF-κB
[38,39]. Therefore, the regulation of COX-2 transcription may be
mediated by aberrant activation of several distinct transcription
factors dependent on agonists [26,50]. These studies suggest that AP-1
and NF-κB play a critical role in the regulation of COX-2 expression in
the development of the inﬂammatory responses. Our data showed
that thrombin-induced COX-2 gene expression and PGE2 release were
signiﬁcantly abolished by a selective AP-1 inhibitor curcumin and NF-
κB inhibitor helenalin (Fig. 8A, B, E, and F), implicating that AP-1 and
NF-κB are involved in thrombin-induced COX-2 expression. Moreover,
thrombin-stimulated AP1-Luc or κB-Luc transcriptional activity was
signiﬁcantly inhibited by curcumin and U0126 or helenalin and
U0126, respectively (Fig. 8D), indicating thrombin-induced activation
of AP-1 and NF-κB was mediated through a MEK/ERK cascade. Our
data further showed that thrombin-stimulated COX-2 transcriptional
activity was signiﬁcantly blocked by GF109203X, PP1, AG1478, U0126,
curcumin, tanshinone IIA (another speciﬁc AP-1 inhibitor), and
helenalin in VSMCs (Fig. 9). These ﬁndings suggested that thrombin-
induced COX-2 expression and PGE2 release is mediated through AP-1
and NF-κB-dependent mechanism via PKC-δ, c-Src, EGFR, and ERK1/2
cascades, consistent with recent studies that COX-2 expression and
prostacyclin release induced by thrombin via ERK, p38MAPK andNF-κB
activation in endothelial cells [16] and COX-2 expression and PGE2
release induced by BK via ERK linking to NF-κB activation in astrocytes
[26]. The involvement of NF-κB and AP-1 in thrombin-induced COX-2
expression and PGE2 release is consistent with a previous report
indicating that both of these transcription factors regulate expression of
target genes involved in various inﬂammatory processes [51].
In conclusion, we reported here that thrombin/PARs system
exerted its inducing effects on COX-2 gene expression and PGE2
release in rat cultured VSMCs. The Gq protein and PTX-sensitive Gi
protein-coupled PAR-1, PKC-δ, c-Src, MMPs, HB-EGF, EGFR, ERK1/2,
AP-1 and NF-κB cascades cooperatively mediated these effects of
thrombin. Based on the observations from literatures and our ﬁndings,
1574 H.-L. Hsieh et al. / Biochimica et Biophysica Acta 1783 (2008) 1563–1575Fig. 10 depicts a model for the signaling mechanisms implicated in
thrombin-induced COX-2 gene expression in rat cultured VSMCs.
These ﬁndings concerning thrombin-induced COX-2 expression
and PGE2 generation imply that thrombin might play an important
role in vascular inﬂammatory diseases, mediated through PKC-δ/c-
Src-dependent activation of MMPs system, EGFR transactivation,
ERK1/2, AP-1 and NF-κB signaling pathways in rat VSMCs. These
results indicated a role for VSMCs, in addition to their contractile
function, as inﬂammatory cells involved in the production of chemical
mediators which may contribute to the inﬂammatory responses seen
in atherosclerosis. Moreover, our data also demonstrated that
thrombin induced PGI2 production in VSMCs (Fig. 1D, insert panel),
which exhibits biological activities potentially beneﬁcial for the pre-
vention of atherothrombosis [52]. In addition, experiments performed
using pharmacological inhibitors (data not shown), we further
showed that thrombin-induced PGI2 synthesis may be mediated
through the similar pathways as PGE2 (Fig. 10). However, there is a
controversy over the COX-2 selective inhibitors for clinical therapeutic
potential [52,53], the new generation of COX-2 inhibitors is still
continually developing to increase their selectivity and improve their
detrimental effects.
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